Similar articles

• Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.

  Suehisa H, Toyooka S, Hotta K, Uchida A, Soh J, Fujiwara Y, Matsuo K, Ouchida M, Takata M, Kiura K, Date H. Suehisa H, et al. J Clin Oncol. 2007 Sep 1;25(25):3952-7. doi: 10.1200/JCO.2007.11.8646. J Clin Oncol. 2007. PMID: 17761979
• A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.

  Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, Ohta M; Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. Kato H, et al. N Engl J Med. 2004 Apr 22;350(17):1713-21. doi: 10.1056/NEJMoa032792. N Engl J Med. 2004. PMID: 15102997 Clinical Trial.
• [UFT in the treatment of primary lung cancer--5-FU concentration in the tissue and side effects].

  Kato H, Inoue S, Takahashi K, Yamanaka A, Okada Y. Kato H, et al. Gan To Kagaku Ryoho. 1987 Jun;14(6 Pt 1):1866-70. Gan To Kagaku Ryoho. 1987. PMID: 3036016 Japanese.
• Adjuvant chemotherapy for non-small-cell lung cancer.

  Pisters KM. Pisters KM. Clin Adv Hematol Oncol. 2003 Sep;1(9):533-7. Clin Adv Hematol Oncol. 2003. PMID: 16258445 Review.
• [Adjuvant chemotherapy for non-small cell lung cancer].

  Okamoto T, Ichinose Y. Okamoto T, et al. Gan To Kagaku Ryoho. 2006 Dec;33(13):1985-90. Gan To Kagaku Ryoho. 2006. PMID: 17197740 Review. Japanese.